

Package leaflet: Information for the patient

Invokana 100 mg film-coated tablets Invokana 300 mg film-coated tablets canagliflozin

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Invokana is and what it is used for
2. What you need to know before you take Invokana
3. How to take Invokana
4. Possible side effects
5. How to store Invokana
6. Contents of the pack and other information

1. What Invokana is and what it is used for

Invokana contains the active substance canagliflozin which belongs to a group of medicines called “blood-glucose lowering drugs.”

“Blood-glucose lowering drugs” are medicines used by adults to treat type 2 diabetes.

This medicine works by increasing the amount of sugar removed from your body in your urine. This reduces the amount of sugar in your blood.

Invokana can be used by itself or along with other medicines you may be using to treat your type 2 diabetes (such as metformin, insulin, a DPP-4 inhibitor [such as sitagliptin, saxagliptin, or linagliptin], a sulphonylurea [such as glimepiride or glipizide], or pioglitazone) that lower blood sugar levels. You may already be taking one or more of these to treat your type 2 diabetes.

It is also important to keep following advice about diet and exercise given by your doctor or nurse.

What is type 2 diabetes?

Type 2 diabetes is a condition in which your body does not make enough insulin, and the insulin that your body produces does not work as well as it should. Your body can also make too much sugar. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical conditions such as heart disease, kidney disease, blindness, and amputation.

2. What you need to know before you take Invokana

Do not take Invokana

- if you are allergic to canagliflozin or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor, pharmacist or nurse before taking this medicine, and during treatment:

- about what you can do to prevent dehydration
- if you have type 1 diabetes (your body does not produce any insulin). Invokana should not be used to treat this condition.
- if you experience rapid weight loss, feeling sick or being sick, stomach pain, excessive thirst, fast and deep breathing, confusion, unusual sleepiness or tiredness, a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat, contact a doctor or the nearest hospital straight away. These symptoms could be a sign of “diabetic ketoacidosis” – a rare but serious, sometimes life-threatening problem you can get with diabetes because of increased levels of “ketone bodies” in your urine or blood, seen in tests. The risk of developing diabetic ketoacidosis may be increased with prolonged fasting, excessive alcohol consumption, dehydration, sudden reductions in insulin dose, or a higher need of insulin due to major surgery or serious illness.
- if you have diabetic ketoacidosis (a complication of diabetes with high blood sugar, rapid weight loss, nausea, or vomiting). Invokana should not be used to treat this condition.
- if you have severe kidney problems or are on dialysis
- if you have severe liver problems
- if you have ever had serious heart disease or if you have had a stroke
- if you are on medicines to lower your blood pressure (anti-hypertensives) or have ever had low blood pressure (hypotension). More information is given below in “Other medicines and Invokana”.
- It is important to check your feet regularly and adhere to any other advice regarding foot care and adequate hydration given by your healthcare professional. You should notify your doctor immediately if you notice any wounds or discolouration, or if you experience any tenderness or pain in your feet. Some studies indicate that taking canagliflozin may have contributed to the risk of lower limb amputation (mainly toe amputations).

If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist, or nurse before taking this medicine.

Kidney function

Your kidneys will be tested by a blood test before you start taking and while you are on this medicine.

Urine glucose

Because of how this medicine works, your urine will test positive for sugar (glucose) while you are on this medicine.

Children and adolescents

Invokana is not recommended for children and adolescents under 18 years.

Other medicines and Invokana

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This is because this medicine can affect the way some other medicines work. Also, some other medicines can affect the way this medicine works.

In particular, tell your doctor if you are taking any of the following medicines:

- other antidiabetics - either insulin or a sulphonylurea (such as gliclazide or glibenclamide) – your doctor may want to reduce your dose in order to avoid your blood sugar level from getting too low (hypoglycaemia)
- medicines used to lower your blood pressure (anti-hypertensives), including diuretics (medicines used to remove levels of excess water in the body, also known as water tablets) since this medicine can also lower your blood pressure by removing levels of excess water in the body. Possible signs of losing too much fluid from your body are listed at the top of section 4 “Possible side effects”.

- St. John's wort (an herbal medicine to treat depression)
- carbamazepine, phenytoin, or phenobarbital (medicines used to control seizures)
- efavirenz or ritonavir (a medicine used to treat HIV infection)
- rifampicin (an antibiotic used to treat tuberculosis)
- cholestyramine (medicine used to reduce cholesterol levels in the blood). See section 3, "Taking this medicine".
- digoxin or digitoxin (medicines used for certain heart problems). The level of digoxin or digitoxin in your blood may need to be checked if taken with Invokana.
- dabigatran (blood thinner medicine that lowers the risk of blood clot formation).

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking or continuing to take this medicine. Invokana should not be used during pregnancy. Talk to your doctor about the best way to discontinue Invokana and control your blood sugar as soon as you know that you are pregnant.

You should not take this medicine if you are breast-feeding. Talk to your doctor about whether to stop taking this medicine or to stop breast-feeding.

Driving and using machines

Invokana has no or negligible influence on the ability to drive, cycle, and use tools or machines. However, dizziness or lightheadedness has been reported, which may affect your ability to drive, cycle, or use tools or machines.

Taking Invokana with other medicines for diabetes called sulphonylureas (such as glimepiride or glipizide) or insulin can increase the risk of having low blood sugar (hypoglycaemia). Signs include blurred vision, tingling lips, trembling, sweating, pale looking, a change in mood, or feeling anxious or confused. This may affect your ability to drive, cycle, and use any tools or machines. Tell your doctor as soon as possible if you get any of the signs of low blood sugar.

Invokana contains lactose

If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

Invokana contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium free'.

3. How to take Invokana

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

How much to take

- The starting dose of Invokana is one 100 mg tablet each day. Your doctor will decide whether to increase your dose to 300 mg.
- Your doctor may limit your dose to 100 mg if you have a kidney problem.
- Your doctor will prescribe the strength that is right for you.

Taking this medicine

- Swallow the tablet whole with a half glass of water.
- You can take your tablet with or without food. It is best to take your tablet before the first meal of the day.
- Try to take it at the same time each day. This will help you remember to take it.

- If your doctor has prescribed canagliflozin along with any bile acid sequestrant such as cholestyramine (medicines for lowering cholesterol) you should take canagliflozin at least 1 hour before or 4 hours to 6 hours after the bile acid sequestrant.

Your doctor may prescribe Invokana together with another glucose-lowering medicinal product. Remember to take all medicines as directed by your doctor to achieve the best results for your health.

Diet and exercise

To control your diabetes, you still need to follow the advice about diet and exercise from your doctor, pharmacist or nurse. In particular, if you are following a diabetic weight control diet, continue to follow it while you are taking this medicine.

If you take more Invokana than you should

If you take more of this medicine than you should, talk to a doctor straight away.

If you forget to take Invokana

- If you forget to take a dose, take it as soon as you remember. However, if it is nearly time for the next dose, skip the missed dose.
- Do not take a double dose (two doses on the same day) to make up for a forgotten dose.

If you stop taking Invokana

Your blood sugar levels may rise if you stop taking this medicine. Do not stop taking this medicine without talking to your doctor first.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Stop taking Invokana and see a doctor as soon as possible if you have any of the following serious side effects:

Dehydration (uncommon, may affect up to 1 in 100 people)

- loss of too much fluid from your body (dehydration). This happens more often in elderly people (aged 75 and over), people with kidney problems, and people taking water tablets (diuretics). Possible signs of dehydration are:
 - feeling light-headed or dizzy
 - passing out (fainting) or feeling dizzy or faint when you stand up
 - very dry or sticky mouth, feeling very thirsty
 - feeling very weak or tired
 - passing little or no urine
 - fast heartbeat.

Contact a doctor or the nearest hospital straight away if you have any of the following side effects:

Diabetic ketoacidosis (rare, may affect up to 1 in 1,000 people)

These are the signs of diabetic ketoacidosis (see also section 2 Warnings and precautions):

- increased levels of “ketone bodies” in your urine or blood
- rapid weight loss
- feeling sick or being sick
- stomach pain
- excessive thirst
- fast and deep breathing
- confusion

- unusual sleepiness or tiredness
- a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat.

This may occur regardless of blood glucose level. The doctor may decide to temporarily or permanently stop the treatment with Invokana.

Tell your doctor as soon as possible if you have any of the following side effects:

Hypoglycaemia (very common, may affect more than 1 in 10 people)

- low blood sugar levels (hypoglycaemia) - when taking this medicine with insulin or a sulphonylurea (such as glimepiride or glipizide).

Possible signs of low blood sugar are:

- blurred vision
- tingling lips
- trembling, sweating, pale looking
- a change in mood or feeling anxious or confused.

Your doctor will tell you how to treat low blood sugar levels and what to do if you have any of the signs above.

Other side effects:

Very common (may affect more than 1 in 10 people)

- vaginal yeast infection.

Common (may affect up to 1 in 10 people)

- rash or redness of the penis or foreskin (yeast infection)
- urinary tract infections
- changes in urination (including urinating more frequently or in larger amounts, urgent need to urinate, need to urinate at night)
- constipation
- feeling thirsty
- nausea
- blood tests may show changes in blood fat (cholesterol) levels and increases in amount of red blood cells in your blood (haematocrit).

Uncommon (may affect up to 1 in 100 people)

- rash or red skin – this may be itchy and include raised bumps, oozing fluid or blisters
- hives
- blood tests may show changes related to kidney function (creatinine or urea) or potassium
- blood tests may show increases in your blood phosphate level
- bone fracture
- kidney failure (mainly as a consequence of loss of too much fluid from your body).
- lower limb amputations (mainly of the toe) especially if you are at high risk of heart disease.

Rare (may affect up to 1 in 1,000 people)

- severe allergic reaction (may include swelling of the face, lips, mouth, tongue, or throat that may lead to difficulty breathing or swallowing).

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.

In the UK, you can also report side effects directly via the Yellow Card Scheme at:

www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

In Ireland, you can also report side effect directly via:

HPRA Pharmacovigilance
Earlsfort Terrace
IRL – Dublin 2
Tel: +353 1 6764971
Fax: +353 1 6762417
Website: www.hpra.ie
E-mail: medsafety@hrpa.ie

In Malta, report side effects to:

ADR Reporting
Website: www.medicinesauthority.gov.mt/adrportal

By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store Invokana

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the blister and carton after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

Do not use Invokana if the packaging is damaged or shows signs of tampering.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Invokana contains

- The active substance is canagliflozin.
 - Each tablet contains 100 mg or 300 mg of canagliflozin.
- The other ingredients are:
 - tablet core: croscarmellose sodium, hydroxypropyl cellulose, lactose anhydrous, magnesium stearate, and microcrystalline cellulose
 - film-coating: macrogol (3350), polyvinyl alcohol, talc, and titanium dioxide (E171). The 100 mg tablet also contains iron oxide yellow (E172).

What Invokana looks like and contents of the pack

- Invokana 100 mg film-coated tablets (tablets) are yellow, capsule-shaped, 11 mm long, with “CFZ” on one side and “100” on the other side.
- Invokana 300 mg film-coated tablets (tablets) are white, capsule-shaped, 17 mm long, with “CFZ” on one side and “300” on the other side.

Invokana is available in PVC/aluminium perforated unit dose blisters. The pack sizes are cartons of 10 x 1, 30 x 1, 90 x 1, or 100 x 1 tablets.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse

Belgium

Manufacturer

Janssen-Cilag SpA
Via C. Janssen
Borgo San Michele
04100 Latina
Italy

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien

Mundipharma Comm VA
Blarenberglaan 3C
B-2800 Mechelen
Tél/Tel: +32 15 45 11 80

Lietuva

UAB "JOHNSON & JOHNSON"
Konstitucijos pr. 21C
LT-08130 Vilnius
Lithuania
Tel: +370 5 278 68 88

България

ТП„Мундифарма медикъл ООД“
ул. „Кораб планина“ № 8
офис 1
София 1407
Тел.: +359 2 962 13 56

Luxembourg/Luxemburg

Mundipharma Comm VA
Blarenberglaan 3C
B-2800 Mechelen
Belgique/Belgien
Tél/Tel: +32 15 45 11 80

Česká republika

Mundipharma GesmbH. Austria - organizační složka ČR
Karolinská 650/1
CZ-186 00 Praha 8 – Karlín
Tel: +420 222 318 221

Magyarország

Janssen-Cilag Kft.
Nagyenyed u. 8-14
H-Budapest, 1123
Tel.: +36 1 884 2858

Danmark

Mundipharma A/S
Frydenlundsvej 30
DK-2950 Vedbæk
Tlf: +45 45 17 48 00

Malta

AM MANGION LTD.
Mangion Building, Triq Ġdida fi Triq Valletta
MT-Ħal-Luqa LQA 6000
Tel: +356 2397 6000

Deutschland

Janssen-Cilag GmbH
Johnson & Johnson Platz 1
D-41470 Neuss
Tel: +49 2137 955-955

Nederland

Mundipharma Pharmaceuticals B.V.
Leusderend 24
NL-3832 RC Leusden
Tel: +31 33 450 82 70

Eesti

UAB "JOHNSON & JOHNSON" Eesti filiaal
Lõõtsa 2
EE-11415 Tallinn
Tel: +372 617 7410

Norge

Janssen-Cilag AS
Postboks 144
NO-1325-Lysaker
Tlf: +47 24 12 65 00

Ελλάδα

Janssen-Cilag Φαρμακευτική Α.Ε.Β.Ε.
Λεωφόρος Ειρήνης 56
GR-151 21 Πεύκη, Αθήνα
Τηλ: +30 210 80 90 000

Österreich

Mundipharma Gesellschaft m.b.H.
Apollongasse 16-18
A-1070 Wien
Tel: +43 1 523 25 05 -0

España

Janssen-Cilag, S.A.
Paseo de las Doce Estrellas, 5-7
E-28042 Madrid
Tel: +34 91 722 81 00

France

Janssen-Cilag
1, rue Camille Desmoulins, TSA 91003
F-92787 Issy Les Moulineaux, Cedex 9
Tél: 0 800 25 50 75 / +33 1 55 00 40 03

Hrvatska

Johnson & Johnson S.E. d.o.o.
Oreškovićeve 6h
10010 Zagreb
Tel: +385 1 6610 700

Ireland

Mundipharma Pharmaceuticals Limited
Millbank House, Arkle Road
Sandyford
IRL-Dublin 18
Tel: +353 1 2063800

Ísland

Janssen-Cilag AB
c/o Vistor hf.
Hörgatúni 2
IS-210 Garðabær
Sími: +354 535 7000

Italia

Mundipharma Pharmaceuticals Srl
Via G. Serbelloni 4
I-20122 Milano
Tel: +39 02 3182881

Κύπρος

Mundipharma Pharmaceuticals Ltd
Οθέλλου 13, Βιομηχανική Περιοχή Ιδαλίου
CY-2540, Λευκωσία
Τηλ: +357 22 815656

Latvija

UAB "JOHNSON & JOHNSON" filiāle Latvijā
Mūkusalas iela 101
Rīga, LV-1004
Tel: +371 678 93561

Polska

Mundipharma Polska Sp. z o.o.
ul. Kochanowskiego 45a
PL – 01-864 Warszawa
Tel.: +48 22 866 87 12

Portugal

Mundipharma Farmacêutica Lda
Lagoas Park - Edifício 8
PT-2740-268 Porto Salvo
Tel: +351 21 90 13 162

România

Johnson & Johnson România SRL
Str. Tipografilor nr. 11-15
Clădirea S-Park, Corp B3-B4, Etaj 3
013714 București
Tel: +40 21 207 1800

Slovenija

Johnson & Johnson d.o.o.
Šmartinska cesta 53
SI-1000 Ljubljana
Tel: +386 1 401 18 00

Slovenská republika

Mundipharma Ges.m.b.H.-o.z.
Svätoplukova 28
SK-821 08 Bratislava
Tel: +421 2 6381 1611

Suomi/Finland

Janssen-Cilag Oy
Vaisalantie/Vaisalavägen 2
FI-02130 Espoo/Esbo
Puh/Tel: +358 207 531 300

Sverige

Mundipharma AB
Mölnsdalsvägen 30B
S-412 63 Göteborg
Tel: +46 31 773 75 30

United Kingdom

Napp Pharmaceuticals Limited,
Cambridge Science Park,
Milton Road,
Cambridge, CB4 0AB
Tel: +44 1223 424444

This leaflet was approved in November 2017.

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site:
<http://www.ema.europa.eu/>.